

AD _____

Award Number: DAMD17-01-1-0348

TITLE: Insulin-Like Growth Factor I Polymorphisms in Breast
Cancer

PRINCIPAL INVESTIGATOR: Rebecca J. Cleveland, M.P.H.
Marilie D. Gammon, Ph.D.
Ralph S. Baric, Ph.D.

CONTRACTING ORGANIZATION: University of North Carolina
Chapel Hill, North Carolina 27599-1350

REPORT DATE: September 2002

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20030317 096

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE September 2002	3. REPORT TYPE AND DATES COVERED Annual Summary (1 Sep 01 -31 Aug 02)	
4. TITLE AND SUBTITLE Insulin-Like Growth Factor I Polymorphisms in Breast Cancer			5. FUNDING NUMBERS DAMD17-01-1-0348	
6. AUTHOR(S): Rebecca J. Cleveland, M.P.H. Marilie D. Gammon, Ph.D. Ralph S. Baric, Ph.D.			8. PERFORMING ORGANIZATION REPORT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of North Carolina Chapel Hill, North Carolina 27599-1350 E-Mail: beck@unc.edu				
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited			12b. DISTRIBUTION CODE	
13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) <p>Insulin-like growth factor I (IGF-I) is an important regulator of growth and differentiation, is known to inhibit apoptosis, is a potent mitogen for human breast cancer cells, and may influence proliferation of the cells of early breast cancer. A number of epidemiologic studies have evaluated the association between plasma IGF-I and breast cancer and have found that pre-menopausal women with higher levels of IGF-I show an elevated risk.</p> <p>Genetic analysis has identified a highly polymorphic region of the IGF-I gene consisting of cytosine-adenine (CA_n) dinucleotide repeats 1 kb upstream from the transcription start site. The relation between circulating IGF-I levels and the polymorphisms has been shown to vary according to the number of these CA repeats. This project is assessing the role of IGF-I polymorphisms in breast cancer, evaluating the relationship between the number of CA repeats in the IGF-I gene and plasma IGF-I levels, and determining if menopausal status confers differential risk of breast cancer in women with particular genotypes.</p> <p>Progress on this project includes completion of laboratory training for techniques used in genotyping DNA samples. Aliquoting of samples has been completed and assay for PCR analysis has been developed and is currently being used to determine genotypes.</p>				
14. SUBJECT TERMS insulin-like growth factor I polymorphism, breast cancer, epidemiology			15. NUMBER OF PAGES 5	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

Table of Contents

	Page Number
Cover.....	1
SF 298.....	2
Table of Contents.....	3
Summary.....	4
Key Research Accomplishments.....	5
Reportable Outcomes.....	5

Insulin-like Growth Factor I Polymorphisms in Breast Cancer

Annual summary report:

This project is investigating a highly polymorphic region of the IGF-I gene consisting of cytosine-adenine (CA_n) dinucleotide repeats 1 kb upstream from the transcription start site. A number of epidemiologic studies have evaluated the association between plasma IGF-I and breast cancer and have found that pre-menopausal women with higher levels of IGF-I show an elevated risk. Also, the relation between circulating IGF-I levels and this IGF-I polymorphism has been shown to vary according to the number of these CA repeats. For this project, the role of IGF-I polymorphisms in breast cancer will be assessed, the relationship between the number of CA repeats in the IGF-I gene and plasma IGF-I levels will be evaluated, and whether menopausal status confers differential risk of breast cancer in women with particular genotypes will be determined.

This project consists of three Tasks. Task 1 was stated to be undertaken in months 1 – 24. Task 1 is still in progress and is on schedule. This task is to genotype genetic polymorphisms of the insulin-like growth factor I gene in 1,087 cases and 1,122 population-based controls on the Long Island Breast Cancer Study Project (Months 1 - 24). For this portion of the study, the majority of the time thus far has been spent in training and development of the polymerase chain reaction (PCR) assay. Intensive laboratory training was completed to learn basic laboratory techniques that would provide a base for the more technical skills that are required to perform PCR analysis. PCR techniques were learned over the course of several months and included the development of the assay that would be used in the genotyping of DNA samples for this project. An optimal assay for the region of interest has recently been developed to work using fluorescently labeled primers. Genotyping of the samples is currently underway and genotypes are being entered into a database.

Task 2 was stated to be completed in months 13 and 14. Task 2 is to conduct validation study of serum IGF-I levels using serum samples from 48 cases and 48 controls. Work on Task 2 will begin in the near future. Task 3 is to perform the final analysis and create final report and is to be carried out in months 24 – 36.

Key Accomplishments:

- Request for and arrival of shipment of 2,209 extracted DNA samples and 100 serum samples of cases and controls from the Long Island Breast Cancer Study Project (LIBCSP) main laboratory located at Columbia University in New York.
- Aliquots made of all 2,209 DNA samples.
- Creation of new laboratory database and assigning the samples new identification numbers in order to blind study personnel of the case-control status of DNA samples.
- Completed laboratory safety course.
- Completed intensive training in laboratory techniques including, but not limited to, PCR assay techniques used in this project to determine IGF-I genotypes, creating acrylamide gels, running PCR products on gels and determining size of fragments. Training for other laboratory techniques include troubleshooting problems that may occur with genotyping reactions and determining what can be done to make the reaction work.
- Developed PCR assay that best amplifies the region of interest for this project using fluorescently tagged primers.
- Genotyping completed on approximately 20 samples that were used during the assay development stage.

Reportable outcomes:

- Poster presentation at the Era of Hope meeting.